<div id=toc></div>

# Table of Contents

- [q-bio.QM](#q-bio.QM) [Total: 2]
- [q-bio.GN](#q-bio.GN) [Total: 2]


<div id='q-bio.QM'></div>

# q-bio.QM [[Back]](#toc)

### [1] [Beyond SMILES: Evaluating Agentic Systems for Drug Discovery](https://arxiv.org/abs/2602.10163)
*Edward Wijaya*

Main category: q-bio.QM

TL;DR: 评估6个药物发现智能体系统在15个任务类别中的泛化能力，发现5个能力差距，并提出下一代框架的设计要求


<details>
  <summary>Details</summary>
Motivation: 评估现有药物发现智能体系统在真实约束条件下的泛化能力，识别能力差距，为下一代框架设计提供指导

Method: 评估6个框架在15个任务类别中的表现，包括肽治疗、体内药理学和资源受限环境；进行配对知识探测实验测试前沿LLMs对肽的理解能力

Result: 发现5个关键能力差距：不支持蛋白质语言模型或肽特异性预测、缺乏体内与计算机数据桥梁、依赖LLM推理而无ML训练或强化学习路径、假设依赖大型制药资源、单目标优化忽略安全-疗效-稳定性权衡。知识探测实验显示瓶颈是架构而非认知能力

Conclusion: 提出下一代药物发现智能体框架的设计要求和能力矩阵，使其能在现实约束下作为计算伙伴发挥作用

Abstract: Agentic systems for drug discovery have demonstrated autonomous synthesis planning, literature mining, and molecular design. We ask how well they generalize. Evaluating six frameworks against 15 task classes drawn from peptide therapeutics, in vivo pharmacology, and resource-constrained settings, we find five capability gaps: no support for protein language models or peptide-specific prediction, no bridges between in vivo and in silico data, reliance on LLM inference with no pathway to ML training or reinforcement learning, assumptions tied to large-pharma resources, and single-objective optimization that ignores safety-efficacy-stability trade-offs. A paired knowledge-probing experiment suggests the bottleneck is architectural rather than epistemic: four frontier LLMs reason about peptides at levels comparable to small molecules, yet no framework exposes this capability. We propose design requirements and a capability matrix for next-generation frameworks that function as computational partners under realistic constraints.

</details>


### [2] [EVA: Towards a universal model of the immune system](https://arxiv.org/abs/2602.10168)
*Ethan Bandasack,Vincent Bouget,Apolline Bruley,Yannis Cattan,Charlotte Claye,Matthew Corney,Julien Duquesne,Karim El Kanbi,Aziz Fouché,Pierre Marschall,Francesco Strozzi*

Main category: q-bio.QM

TL;DR: EVA是首个跨物种、多模态的免疫学和炎症基础模型，整合转录组学和病理学数据，在药物开发全流程的39个任务上实现最先进性能。


<details>
  <summary>Details</summary>
Motivation: 将基础模型有效应用于免疫介导疾病的转化研究需要能够捕捉多细胞相互作用产生的复杂表型的多模态患者表征，而现有生物基础模型大多仅关注单细胞分辨率，且评估指标与药物开发实际任务脱节。

Method: 开发跨物种、多模态免疫学基础模型EVA，整合跨物种、平台和分辨率的转录组学数据以及病理学数据，建立缩放定律，并设计包含39个任务的综合评估套件，涵盖药物开发全流程。

Result: EVA在药物开发管道的各个任务类别（零样本靶点功效预测、基因功能预测、跨物种分子扰动、患者分层、治疗反应预测等）上均实现了最先进的性能，并识别出具有生物学意义的特征。

Conclusion: EVA作为首个跨物种多模态免疫学基础模型，能够生成丰富的统一患者表征，在药物开发全流程任务上表现优异，其开放版本将加速免疫介导疾病的研究。

Abstract: The effective application of foundation models to translational research in immune-mediated diseases requires multimodal patient-level representations that can capture complex phenotypes emerging from multicellular interactions. Yet most current biological foundation models focus only on single-cell resolution and are evaluated on technical metrics often disconnected from actual drug development tasks and challenges. Here, we introduce EVA, the first cross-species, multimodal foundation model of immunology and inflammation, a therapeutic area where shared pathogenic mechanisms create unique opportunities for transfer learning. EVA harmonizes transcriptomics data across species, platforms, and resolutions, and integrates histology data to produce rich, unified patient representations. We establish clear scaling laws, demonstrating that increasing model size and compute translates to improvements in both pretraining and downstream tasks performance. We introduce a comprehensive evaluation suite of 39 tasks spanning the drug development pipeline: zero-shot target efficacy and gene function prediction for discovery, cross-species or cross-diseases molecular perturbations for preclinical development, and patient stratification with treatment response prediction or disease activity prediction for clinical trials applications. We benchmark EVA against several state-of-the-art biological foundation models and baselines on these tasks, and demonstrate state-of-the-art results on each task category. Using mechanistic interpretability, we further identify biological meaningful features, revealing intertwined representations across species and technologies. We release an open version of EVA for transcriptomics to accelerate research on immune-mediated diseases.

</details>


<div id='q-bio.GN'></div>

# q-bio.GN [[Back]](#toc)

### [3] [Validating Interpretability in siRNA Efficacy Prediction: A Perturbation-Based, Dataset-Aware Protocol](https://arxiv.org/abs/2602.10152)
*Zahra Khodagholi,Niloofar Yousefi*

Main category: q-bio.GN

TL;DR: 该论文提出了一种名为"预合成门"的协议，用于验证siRNA功效预测中显著性图作为设计指导的可靠性，发现两种失败模式，并开发了生物学先验正则化方法来提高显著性忠实度。


<details>
  <summary>Details</summary>
Motivation: 显著性图越来越多地被用作siRNA功效预测的设计指导，但在进行序列编辑之前，归因方法很少经过验证。需要一种方法来测试突变高显著性位置是否比组成匹配的对照更能改变模型输出。

Method: 引入"预合成门"协议，通过反事实敏感性忠实度测试来验证显著性图。使用跨数据集转移分析，识别失败模式。开发了生物学先验正则化器（BioPrior）来增强显著性忠实度。

Result: 在四个基准测试中，19/20的折叠实例通过验证；单个失败案例显示倒置显著性。在mRNA水平测定上训练的模型在荧光素酶报告数据集上崩溃，表明协议转换可能无声地使部署失效。BioPrior正则化器以适度的预测权衡为代价增强了显著性忠实度。

Conclusion: 研究结果表明，显著性验证是解释引导治疗设计中必不可少的预部署实践。生物学先验正则化可以改善显著性忠实度，但需要在预测性能和解释可靠性之间进行权衡。

Abstract: Saliency maps are increasingly used as \emph{design guidance} in siRNA efficacy prediction, yet attribution methods are rarely validated before motivating sequence edits. We introduce a \textbf{pre-synthesis gate}: a protocol for \emph{counterfactual sensitivity faithfulness} that tests whether mutating high-saliency positions changes model output more than composition-matched controls. Cross-dataset transfer reveals two failure modes that would otherwise go undetected: \emph{faithful-but-wrong} (saliency valid, predictions fail) and \emph{inverted saliency} (top-saliency edits less impactful than random). Strikingly, models trained on mRNA-level assays collapse on a luciferase reporter dataset, demonstrating that protocol shifts can silently invalidate deployment. Across four benchmarks, 19/20 fold instances pass; the single failure shows inverted saliency. A biology-informed regularizer (BioPrior) strengthens saliency faithfulness with modest, dataset-dependent predictive trade-offs. Our results establish saliency validation as essential pre-deployment practice for explanation-guided therapeutic design. Code is available at https://github.com/shadi97kh/BioPrior.

</details>


### [4] [STRAND: Sequence-Conditioned Transport for Single-Cell Perturbations](https://arxiv.org/abs/2602.10156)
*Boyang Fu,George Dasoulas,Sameer Gabbita,Xiang Lin,Shanghua Gao,Xiaorui Su,Soumya Ghosh,Marinka Zitnik*

Main category: q-bio.GN

TL;DR: STRAND是一个生成模型，通过编码调控DNA序列来预测单细胞转录响应，支持零样本推理，将基因组覆盖率从~1.5%扩展到~95%


<details>
  <summary>Details</summary>
Motivation: 现有基因水平扰动模型将针对同一基因的不同干预（不同转录起始位点和调控元件）合并为相同表示，无法区分这些差异。需要一种能考虑基因组位置特异性影响的模型。

Method: STRAND通过编码扰动位点的基因组序列来表示扰动，使用这个表示来参数化从对照到扰动细胞状态的条件传输过程。基于序列而非固定基因标识符，支持训练中未见位点的零样本推理。

Result: 在K562、Jurkat和RPE1细胞的CRISPR扰动数据集上评估，STRAND在低样本情况下提升判别分数达33%，在未见基因扰动基准上获得最佳平均排名，跨细胞系转移提升Pearson相关性达0.14。

Conclusion: STRAND通过序列条件化和传输过程显著提升扰动预测能力，能够解析基因水平模型遗漏的功能性替代转录起始位点，将基因组覆盖率从~1.5%扩展到~95%。

Abstract: Predicting how genetic perturbations change cellular state is a core problem for building controllable models of gene regulation. Perturbations targeting the same gene can produce different transcriptional responses depending on their genomic locus, including different transcription start sites and regulatory elements. Gene-level perturbation models collapse these distinct interventions into the same representation.
  We introduce STRAND, a generative model that predicts single-cell transcriptional responses by conditioning on regulatory DNA sequence. STRAND represents a perturbation by encoding the sequence at its genomic locus and uses this representation to parameterize a conditional transport process from control to perturbed cell states. Representing perturbations by sequence, rather than by a fixed set of gene identifiers, supports zero-shot inference at loci not seen during training and expands inference-time genomic coverage from ~1.5% for gene-level single-cell foundation models to ~95% of the genome.
  We evaluate STRAND on CRISPR perturbation datasets in K562, Jurkat, and RPE1 cells. STRAND improves discrimination scores by up to 33% in low-sample regimes, achieves the best average rank on unseen gene perturbation benchmarks, and improves transfer to novel cell lines by up to 0.14 in Pearson correlation. Ablations isolate the gains to sequence conditioning and transport, and case studies show that STRAND resolves functionally alternative transcription start sites missed by gene-level models.

</details>
